Private Market View

Jinkai Biotechnology

Chengdu, China · Founded 2008 · Acquired/Merged (Operating Subsidiary)

Last price · $/share
Implied valuation
$9.4M
Total raised
Last round

Key facts

  • Jinkai Biotechnology’s last known valuation is $9.4M (Nov 2014).
  • Notable investors include Sichuan Development Holding.
  • Status: Acquired/Merged (Operating Subsidiary).
Free account
See the evidence behind this price
  • ·The complete investor list — 1 names
  • ·Watchlist + deal alerts for Jinkai Biotechnology
  • ·The full record, as it builds
Create free account
No card required

Funding rounds

No rounds on record

No funding rounds for Jinkai Biotechnology are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.

Pro members can request priority coverage with a 48-hour turnaround.

About Jinkai Biotechnology

Manufacturer of biological products catering to agriculture, food, environmental protection, daily chemical, and pharmaceutical industries. The company offers advanced, research-driven formulations, environmentally friendly production processes, and versatile product lines for the agricultural, food, environmental protection, daily chemical, and pharmaceutical sectors, enabling businesses to improve operational performance, reduce their ecological footprint, and meet safety standards in diverse markets.

Sector
Healthcare
HQ
Chengdu, China
Founded
2008
Employees
100
Ownership
Acquired/Merged (Operating Subsidiary)
PA Mark — not yet priced

Jinkai Biotechnology doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.

Pro members can request priority coverage with a 48-hour turnaround.

Recorded secondary trades

No prints on record

No secondary trades in Jinkai Biotechnology shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.

Pro members can request priority coverage with a 48-hour turnaround.

Institutional fund marks

No fund marks yet

No SEC-registered fund has reported a fair-value mark on Jinkai Biotechnology in its N-PORT filings yet. We sweep new filings monthly.

Pro members can request priority coverage with a 48-hour turnaround.